Advanced search
Publication Cover
Immunotherapy Volume 4, 2012 - Issue 2
Submit an article Journal homepage
746
Views
0
CrossRef citations to date
0
Altmetric
Review

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Francesco Panzaa Geriatric Unit & Gerontology-Geriatric Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, ItalyView further author information
,
Vincenza Frisardia Geriatric Unit & Gerontology-Geriatric Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, ItalyView further author information
,
Vincenzo Solfrizzib Department of Geriatrics, Center for Aging Brain, University of Bari, Bari, ItalyView further author information
,
Bruno P Imbimboc Research & Development Department, Chiesi Farmaceutici, Parma, ItalyView further author information
,
Giancarlo Logroscinod Department of Neurological & Psychiatric Sciences, University of Bari, Bari, ItalyView further author information
,
Andrea Santamatoe Department of Physical Medicine & Rehabilitation, University of Foggia, Foggia, ItalyView further author information
,
Antonio Grecof Geriatric Unit & Gerontology-Geriatric Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, Italy1View further author information
,
Davide Seripag Geriatrics Unit, Azienda ULSS 16 Padova, S Antonio Hospital, Padova, ItalyView further author information
&
Alberto Pilottof Geriatric Unit & Gerontology-Geriatric Research Laboratory, IRCCS Casa Sollievo della Sofferenza, Foggia, Italy1;g Geriatrics Unit, Azienda ULSS 16 Padova, S Antonio Hospital, Padova, ItalyView further author information
 show all
Pages 213-238 | Published online: 17 Feb 2012

References

  • Qiu C , KivipeltoM, von Strauss E. Epidemiology of Alzheimer‘s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci.11(2) , 111–128 (2009).
  • Thies W , Bleiler L; Alzheimer‘s Association. 2011 Alzheimer‘s disease facts and figures. Alzheimers Dement.7(2) , 208–244 (2011).
  • Frisardi V , SolfrizziV, ImbimboPB et al. Towards disease-modifying treatment of Alzheimer‘s disease: drugs targeting beta-amyloid. Curr. Alzheimer Res. 7(1) , 40–55 (2010).
  • Panza F , SolfrizziV, FrisardiV et al. Disease-modifying approach to the treatment of Alzheimer‘s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26(7) , 537–555 (2009).
  • Panza F , SolfrizziV, FrisardiV et al. Beyond the neurotransmitter-focused approach in treating Alzheimer‘s disease: drugs targeting beta-amyloid and tau protein. Aging Clin. Exp. Res. 21(6) , 386–406 (2009).
  • Alzheimer A . On a peculiar disease of the cerebral cortex. Allgemeine Zeitschrift fur Psychiatrie und Psychish-Gerichtlich Medicin64 , 146–148 (1907).
  • Khachaturian ZS . Diagnosis of Alzheimer‘s disease. Arch. Neurol.42(11) , 1097–1105 (1985).
  • Mirra SS , HeymanA, McKeelD et al. The consortium to establish a registry for Alzheimer‘s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer‘s disease. Neurology 41(4) , 479–486 (1991).
  • Newell KL , HymanBT, GrowdonJH, Hedley-WhyteET. Application of the National Institute on Aging (NIA)–Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J. Neuropathol. Exp. Neurol.58(11) , 1147–1155 (1999).
  • Su JH , CummingsBJ, CotmanCW. Early phosphorylation of tau in Alzheimer‘s disease occurs at Ser-202 and is preferentially located within neurites. NeuroReport5(17) , 2358–2362 (1994).
  • Su JH , CummingsBJ, CotmanCW. Plaque biogenesis in brain aging and Alzheimer‘s disease: I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res.739(1–2) , 79–87 (1996).
  • Graeber MB , KoselS, EgenspergerR et al. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1(1) , 73–80 (1997).
  • Small SA , DuffK. Linking Aβ and tau in late-onset Alzheimer‘s disease: a dual pathway hypothesis. Neuron60(4) , 534–542 (2008).
  • Walter J , KaetherC, SteinerH, HaassC. The cell biology of Alzheimer‘s disease: uncovering the secrets of secretases. Curr. Opin. Neurobiol.11(5) , 585–590 (2001).
  • Seubert P , Vigo-PelfryC, EschF et al. Isolation and quantification of soluble Alzheimer‘s β-peptide from biological fluids. Nature 359(6393) , 325–327 (1996).
  • Iwatsubo T , OdakaA, SuzukiN, MizusawaH, NukinaN, IharaY. Visualization of Ab42(43) and Ab40 in senile plaques with specific Ab monoclonals: evidence that the initially deposited species is Ab42(43). Neuron13(1) , 45–53 (1993).
  • Hardy J , AllsopD. Amyloid deposition as the central event in the aetiology of Alzheimer‘s disease. Trends Pharmacol. Sci.12(5) , 383–388 (1991).
  • Armstrong RA . The pathogenesis of Alzheimer‘s disease: a reevaluation of the “Amyloid Cascade Hypothesis”. Int. J. Alzheimers Dis.2011 , 630865 (2011)
  • Giasson BI , LeeVMY, TrojanowskiJQ. Interactions of amyloidogenic proteins. Neuromolecular Med.4(1–2) , 49–58 (2003).
  • Smith MA , SiedlakSL, RicheyPL et al. Tau protein directly interacts with the amyloid β-protein precursor: implications for Alzheimer‘s disease. Nat. Med. 1(4) , 365–369 (1995).
  • Oyama F , ShimadaH, OyamaR, TitaniK, IharaY. β-amyloid protein precursor and τ mRNA levels versus β-amyloid plaque and neurofibrillary tangles in the aged human brain. J. Neurochem.60(5) , 1658–1664 (1993).
  • Shankar GM , LiS, MehtaTH et al. Amyloid-β protein dimers isolated directly from Alzheimer‘s brains impair synaptic plasticity and memory. Nat. Med. 14(8) , 837–842 (2008).
  • Selkoe DJ . Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res.192(1) , 106–113 (2008).
  • Koffie RM , Meyer-LuehmannM, HashimotoT et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106(10) , 4012–4017 (2009).
  • Shankar GM , BloodgoodBL, TownsendM, WalshDM, SelkoeDJ, SabatiniBL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci.27(11) , 2866–2875 (2007).
  • Lesnè S , KohMT, KotilinekL et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440(7082) , 352–357 (2006).
  • Imbimbo BP , PanzaF, FrisardiV et al. Therapeutic intervention for Alzheimer‘s disease with γ-secretase inhibitors: still a viable option? Expert Opin. Investig. Drugs 20(3) , 325–341 (2011).
  • Vellas B , SolO, SnyderP et al. EHT0202 in Alzheimer‘s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr. Alzheimer Res. 8(2) , 203–212 (2011).
  • Lannfelt L , BlennowK, ZetterbergH et al.; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer‘s disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol.7(9) , 779–786 (2008).
  • Faux NG , RitchieCW, GunnA et al. PBT2 rapidly improves cognition in Alzheimer‘s disease: additional Phase II analyses. J. Alzheimers Dis. 20(2) , 509–516 (2010).
  • Wisniewski T , KonietzkoU. Amyloid-beta immunisation for Alzheimer‘s disease. Lancet Neurol.7(9) , 805–811 (2008).
  • Cribbs DH . Abeta DNA vaccination for Alzheimer‘s disease: focus on disease prevention. CNS Neurol. Disord. Drug Targets9(2) , 207–216 (2010).
  • Takashima A . TAU aggregation is a therapeutic target for Alzheimer‘s disease. Curr. Alzheimer Res.7(8) , 665–669 (2010).
  • Lace GL , WhartonSB, IncePG. A brief history of tau: the evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin. Neuropathol.26(2) , 43–58 (2007).
  • Clark CM , XieS, ChittamsJ et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 60(12) , 1696–1702 (2003).
  • Sahara N , MaedaS, MurayamaM et al. Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur. J. Neurosci. 25(10) , 3020–3029 (2007).
  • Kimura T , FukudaT, SaharaN et al. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285(49) , 38692–38699 (2010).
  • Maeda S , SaharaN, SaitoY et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 46(12) , 3856–3861 (2007).
  • Arriagada PV , GrowdonJH, Hedley-WhyteET, HymanBT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer‘s disease. Neurology42(3 Pt 1) , 631–639 (1992).
  • Tariot PN , AisenPS. Can lithium or valproate untie tangles in Alzheimer‘s disease? J. Clin. Psychiatry70(6) , 919–921 (2009).
  • Medina M . Recent developments in tau-based therapeutics for neurodegenerative diseases. Recent Pat. CNS Drug Discov.6(1) , 20–30 (2011).
  • Haass C , SelkoeDJ. Protein oligomers in neurodegeneration: lessons from the Alzheimer‘s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol.8(2) , 101–112 (2007).
  • Iqbal K , LiuF, GongCX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol.118(1) , 53–69 (2009).
  • Brunden KR , TrojanowskiJQ, LeeVM. Advances in tau-focused drug discovery for Alzheimer‘s disease and related tauopathies. Nat. Rev. Drug Discov.8(10) , 783–793 (2009).
  • Andorfer C , AckerCM, KressY, HofPR, DuffK, DaviesP. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci.25(22) , 5446–5454 (2005).
  • de Calignon A , Spires-JonesTL, PitstickR, CarlsonGA, HymanBT. Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol.68(7) , 757–761 (2009).
  • Grill JD , CummingsJL. Current therapeutic targets for the treatment of Alzheimer‘s disease. Expert Rev. Neurother.10(5) , 711–728 (2010).
  • Bulic B , PickhardtM, MandelkowEM, MandelkowE. Tau protein and tau aggregation inhibitors. Neuropharmacology59(4–5) , 276–289 (2010).
  • Necula M , ChiritaCN, KuretJ. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry44(30) , 10227–10237 (2005).
  • Pickhardt M , BiernatJ, KhlistunovaI et al. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr. Alzheimer Res.4(4) , 397–402 (2007).
  • Bulic B , PickhardtM, KhlistunovaI et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. Engl. 46(48) , 9215–9219 (2007).
  • Pickhardt M , LarbigG, KhlistunovaI et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46 , 10016–10023 (2007).
  • Pickhardt M , GazovaZ, von Bergen M et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer‘s paired helical filaments in vitro and in cells. J. Biol. Chem.280(5) , 3628–3635 (2005).
  • Crowe A , HuangW, BallatoreC et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48(32) , 7732–7745 (2009).
  • Buchholz K , SchirmerRH, EubelJK et al. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52(1) , 183–191 (2008).
  • Wischik CM , BenthamP, WischikDJ, SengKM. Tau aggregation inhibitor (TAI) therapy with Rember™ arrests disease progression in mild and moderate Alzheimer‘s disease over 50 weeks. Alzheimers Dement.4(Suppl. 1) , T167 (2008).
  • O‘Leary JC 3rd, Li Q, Marinec P et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener.5 , 45 (2010).
  • Wischik C , StaffR. Challenges in the conduct of disease-modifying trials in AD: practical experience from a Phase 2 trial of tau-aggregation inhibitor therapy. J. Nutr. Health Aging13(4) , 367–369 (2009).
  • Staff RT , AhearnTS, MurrayAD et al. Tau aggregation inhibitor (TAI) therapy with Rember™ arrests the trajectory of rCBF decline in brain regions affected by tau pathology in mild and moderate Alzheimer‘s disease (AD). Alzheimers Dement. 4(Suppl. 2) , T775 (2008).
  • Murray AD , StaffRT, AhearnTS et al. Tau aggregation inhibitor (TAI) therapy with Rember™ changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer‘s disease (AD). Alzheimers Dement. 4(Suppl. 2) , T786 (2008).
  • Masuda M , SuzukiN, TaniguchiS et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45(19) , 6085–6094 (2009).
  • Schneider A , MandelkowE. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics5(3) , 443–457 (2008).
  • Illenberger S , Zheng-FischhoferQ, PreussU et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer‘s disease. Mol. Biol. Cell 9(6) , 1495–1512 (1998).
  • Wen Y , PlanelE, HermanM et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28(10) , 2624–2632 (2008).
  • Plattner F , AngeloM, GieseKP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem.281(35) , 25457–25465 (2006).
  • Porsteinsson AP , TariotPN, ErbR, GaileS. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am. J. Geriatr. Psychiatry5(4) , 344–351 (1997).
  • Porsteinsson AP , TariotPN, JakimovichLJ et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 11(4) , 434–440 (2003).
  • Leyhe T , EschweilerGW, StranskyE et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer‘s disease. J. Alzheimers Dis. 16(3) , 649–656 (2009).
  • Hampel H , EwersM, BurgerK et al. Lithium trial in Alzheimer‘s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 70(6) , 922–931 (2009).
  • Tariot PN , AisenP, CummingsJ et al. The ADCS valproate neuroprotection trial: primary efficacy and safety results. Alzheimer‘s Dement. 5(4) , P84–P85 (2009).
  • Gong CX , IqbalK. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem.15(23) , 2321–2328 (2008).
  • Kins S , CrameriA, EvansDR, HemmingsBA, NitschRM, GotzJ. Reduced protein phosphatise 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem.276(41) , 38193–38200 (2001).
  • Arendt T , HolzerM, FruthR, BrucknerMK, GartnerU. Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience69(3) , 691–698 (1995).
  • Iqbal K , Alonso Adel C, El-Akkad E et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci.19(1–2) , 95–99 (2002).
  • Tanimukai H , KudoT, TanakaT, Grundke-IqbalI, IqbalK, TakedaM. Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics9(2) , 103–109 (2009).
  • Golde TE , PetrucelliL, LewisJ. Targeting Abeta and tau in Alzheimer‘s disease, an early interim report. Exp. Neurol.223(2) , 252–266 (2010).
  • Bassan M , ZamostianoR et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72(3) , 1283–1293 (1999).
  • Stewart AJ , FoxA, MorimotoBH, GozesI. Looking for novel ways to treat the hallmarks of Alzheimer‘s disease. Expert Opin. Investig. Drugs16(8) , 1183–1196 (2007).
  • Gozes I , GiladiE, PinhasovA, BardeaA, BrennemanDE. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther.293(3) , 1091–1098 (2000).
  • Kennedy GJ , GoldeTE, TariotPN, CummingsJL. Amyloid-based interventions in Alzheimer‘s disease. CNS Spectr.12(Suppl. 1) , 1–14 (2007).
  • Schenk D , BarbourR, DunnW et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740) , 173–177 (1999).
  • Morgan D , DiamondD, GottschallP et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer‘s disease. Nature 408(6815) , 982–985 (2000).
  • Wang CM , DevriesS, CamboniM, GlassM, MartinPT. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer‘s disease. Neurobiol. Dis.39(3) , 409–422 (2010).
  • Wiessner C , WiederholdKH, TissotAC et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 31(25) , 9323–9331 (2011).
  • Sigurdsson EM , ScholtzovaH, MehtaP, FrangioneB, WisniewskiT. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer‘s disease associated pathology in transgenic mice. Am. J. Pathol.159(2) , 439–447 (2001).
  • Maier M , SeabrookTJ, LazoND et al. Short amyloid beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer‘s disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26(18) , 4717–4728 (2006).
  • Frenkel D , KatzO, SolomonB. Immunization against Alzheimer‘s beta -amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA97(21) , 11455–11459 (2000).
  • Bard F , CannonC, BarbourR et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8) , 916–919 (2000).
  • Cattepoel S , HanenbergM, KulicL, NitschRM. Chronic intranasal treatment with an anti-Aβ(30–42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer‘s disease. PLoS ONE6(4) , e18296 (2011).
  • Bacskai BJ , KajdaszST, ChristieRH et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7(3) , 369–372 (2001).
  • Solomon B , KoppelR, HananE, KatzavT. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl Acad. Sci. USA93(1) , 452–455 (1996).
  • Das P , HowardV, LoosbrockN, DicksonD, MurphyMP, GoldeTE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci.23(24) , 8532–8538 (2003).
  • Sigurdsson EM , KnudsenE, AsuniA et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer‘s disease mouse model immunized with amyloid-β derivatives. J. Neurosci. 24(28) , 6277–6282 (2004).
  • Brody DL , HoltzmanDM. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci.31 , 175–193 (2008).
  • Rosenmann H , GrigoriadisN, KarussisD et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63(10) , 1459–1467 (2006).
  • Boimel M , GrigoriadisN, LourbopoulosA et al. Efficacy safety of immunization with phosphorylated tau against neurofibrillary and tangles in mice. Exp. Neurol. 224(2) , 472–485 (2010).
  • Novak M . Tau vaccine: active immunization with misfloded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement.5(Suppl. 1) , P93 (2009) (Abstract).
  • Zilka N , KontsekovaE, NovakM. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J. Alzheimers Dis.15(2) , 169–179 (2008).
  • Kontsekova E , IvanovovaN, HandzusovaM, NovakM. Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. Cell. Mol. Neurobiol.29(6–7) , 793–798 (2009).
  • Bretteville A , PlanelE. Tau aggregates: toxic, inert, or protective species? J. Alzheimers Dis.14(4) , 431–436 (2008).
  • Congdon EE , DuffKE. Is tau aggregation toxic or protective? J. Alzheimers Dis.14(4) , 453–457 (2008).
  • Kayed R , JacksonGR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr. Opin. Immunol.21(3) , 359–363 (2009)
  • Walsh DM , SelkoeDJ. Abeta oligomers – a decade of discovery. J. Neurochem.101(5) , 1172–1184 (2007).
  • Bayer AJ , BullockR, JonesRW et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64(1) , 94–101 (2005).
  • Pride M , SeubertP, GrundmanM, HagenM, EldridgeJ, BlackRS. Progress in the active immunotherapeutic approach to Alzheimer‘s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis.5(3–4) , 194–196 (2008).
  • Orgogozo JM , GilmanS, DartiguesJF et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1) , 46–54 (2003).
  • Ferrer I , Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer‘s disease. Brain Pathol.14(1) , 11–20 (2004).
  • Nicoll JA , WilkinsonD, HolmesC, SteartP, MarkhamH, WellerRO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide. a case report. Nat. Med.9(4) , 448–452 (2003).
  • Fisher Y , NemirovskyA, BaronR, MonsonegoA. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer‘s disease. PLoS ONE 26, 5(5) , e10830 (2010).
  • Bombois S , MaurageCA, GompelM et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol. 64(4) , 583–587 (2007).
  • Masliah E , HansenL, AdameA et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64(1) , 129–131 (2005).
  • Hock C , KonietzkoU, StrefferJR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer‘s disease. Neuron 38(4) , 547–554 (2003).
  • Holmes C , BocheD, WilkinsonD et al. Long-term effects of Aβ42 immunisation in Alzheimer‘s disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 372(9634) , 216–223 (2008).
  • Götz J , ChenF, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Aβ42 fibrils. Science293(5534) , 1491–1495 (2001).
  • Knopman DS , ParisiJE, SalviatiA et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62(11) , 1087–1095 (2003).
  • Oddo S , BillingsL, KesslakJP, CribbsDH, LaFerlaFM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron43(3) , 321–332 (2004).
  • Tabira T . Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J. Exp. Med.220(2) , 95–106 (2010).
  • Lemere CA , MasliahE. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat. Rev. Neurol.6(2) , 108–119 (2010).
  • Das P , MurphyM, YounkinL, YounkinS, GoldeT. Reduced effectiveness of Aβ1–42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging22(5) , 721–727 (2010).
  • Frenkel D , DewachterI, van Leuven F, Solomon B. Reduction of β-amyloid plaques in brain of transgenic mouse model of Alzheimer‘s disease by EFRH-phage immunization. Vaccine21(11–12) , 1060–1065 (2003).
  • Agadjanyan MG , GhochikyanA, PetrushinaI et al. Prototype Alzheimer‘s disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174(3) , 1580–1586 (2005).
  • Petrushina I , GhochikyanA, MktrichyanM et al. Alzheimer‘s disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice. J. Neurosci. 27(46) , 12721–12731 (2007).
  • Bowers WJ , MastrangeloMA, StanleyHA, CaseyAE, MiloLJ Jr, Federoff HJ. HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigenspecific immune responses. Neurobiol. Aging26(4) , 393–407 (2005).
  • Okura Y , MiyakoshiA, KohyamaK, ParkIK, StaufenbielM, MatsumotoY. Nonviral Abeta DNA vaccine therapy against Alzheimer‘s disease: long-term effects and safety. Proc. Natl Acad. Sci. USA103(25) , 9619–9624 (2006).
  • Movsesyan N , GhochikyanA, MkrtichyanM et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine–a novel immunotherapeutic strategy. PLoS ONE 3 , e2124 (2008).
  • Bach P , TschäpeJA, KopietzF et al. Vaccination with Aβ-displaying virus-like particles reduces soluble and insoluble cerebral Aβ and lowers plaque burden in APP transgenic mice. J. Immunol. 182(12) , 7613–7624 (2008).
  • Lemere CA , MaronR, SpoonerET et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 920 , 328–331 (2000).
  • Zhang J , WuX, QinC et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer‘s disease. Neurobiol. Dis. 14(3) , 365–379 (2003).
  • Frenkel D , PuckettL, PetrovicS et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol. 63(5) , 591–601 (2008).
  • Weiner HL , LemereCA, MaronR et al. Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer‘s disease. Ann. Neurol. 48(4) , 567–579 (2000).
  • Asuni AA , BoutajangoutA, QuartermainD, SigurdssonEM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci.27(34) , 9115–9129 (2007).
  • Lewis J , McGowanE, RockwoodJ et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 5(4) , 402–405 (2000).
  • Rosenmann H , GrigoriadisN, Eldar-LevyH et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 212(1) , 71–78 (2008).
  • Sigurdsson EM , QuatermainD, BoutajangoutA. Tau immunotherapy prevents cognitive decline and clears pathological tau in a tangle mouse model. Alzheimeirs Dement.4(Suppl. 1) , T191 (2008).
  • Khrisnamurthy PK , SaitHBR, BoutajangoutA, SigurdssonEM. Immunotherapy targeting Alzheimer‘s phosphor-tau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a mouse model of tauopathy. Alzheimeirs Dement.5(Suppl. 1) , P112 (2009).
  • Andorfer C , KressY, EspinozaM et al. Hyperphosphsorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86(3) , 582–590 (2003).
  • Boutajangout A , FrangioneB, BrionJP, WisniewskyT, SigurdssonEM. Presenilin 1 mutation promotes tau phosphorylation and aggregation in a novel Alzheimer‘s disease mouse model. Alzheimeirs Dement.4(Suppl. 1) , T185 (2008).
  • Wisniewski T , SigurdssonEM. Murine models of Alzheimer‘s disease and their use in developing immunotherapies. Biochim. Biophys. Acta1802(10) , 847–859 (2010).
  • Kayed R . Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum. Vaccin.6(11) , 931–935 (2010).
  • Jicha GA . Is passive immunization for Alzheimer‘s disease ‘alive and well‘ or ‘dead and buried‘? Expert Opin. Biol. Ther.9 , 481–491 (2009).
  • Panza F , FrisardiV, ImbimboBP, SeripaD, SolfrizziV, PilottoA. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer‘s disease: the Aβ target at a crossroads. Expert Opin. Biol. Ther.11(6) , 679–686 (2011).
  • Morgan D . Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener. Dis.2(5) , 261–266 (2005).
  • Lichtlen P , MohajeriMH. Antibody-based approaches in Alzheimer‘s research: safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem.104(4) , 859–874 (2008).
  • Walsh DM , SelkoeDJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett.11(4) , 213–228 (2004).
  • Kerchner GA , BoxerAL. Bapineuzumab. Expert Opin. Biol. Ther.10(7) , 1121–1130 (2010).
  • Panza F , FrisardiV, ImbimboBP et al. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer‘s disease. Immunotherapy 2(6) , 767–782 (2010).
  • Panza F , FrisardiV, ImbimboBP et al. Anti-β-Amyloid immunotherapy for Alzheimer‘s disease: focus on bapineuzumab. Curr. Alzheimer Res. 8(8) , 808–817 (2011).
  • Samadi H , SultzerD. Solanezumab for Alzheimer‘s disease. Expert Opin. Biol. Ther.11(6) , 787–798 (2011).
  • Pul R , DodelR, StangelM. Antibody-based therapy in Alzheimer‘s disease. Expert Opin. Biol. Ther.11(3) , 343–357 (2011).
  • Mamikonyan G , NeculaM, MkrtichyanM et al. Anti-A beta1–11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 282(31) , 22376–22386 (2007).
  • Bacskai BJ , KajdaszST, McLellanME et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22(18) , 7873–7878 (2002).
  • Tamura Y , HamajimaK, MatsuiK et al. The F(ab)‘2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis. 20(2) , 541–549 (2005)
  • Johnson-Wood K , LeeM, MotterR et al. Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer‘s disease. Proc. Natl Acad. Sci. USA 94(4) , 1550–1555 (1997).
  • Black RS , SperlingRA, SafirsteinB et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 24(2) , 198–203 (2010).
  • Salloway S , SperlingR, GilmanS et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24) , 2061–2070 (2009).
  • Rinne JO , BrooksDJ, RossorMN et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer‘s disease treated with bapineuzumab: a Phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9(4) , 363–372 (2010).
  • Rabinovici GD , JagustWJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol.21(1) , 117–128 (2009).
  • Blennow K , ZetterbergH, WeiJ, LiuE, BlackR, GrundmanM. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer‘s disease. Alzheimers Dement.6(Suppl.) , S134–S135 (2010).
  • Laskowitz DT , VitekMP. Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics8(8) , 959–969 (2008).
  • Kim J , BasakJM, HoltzmanDM. The role of apolipoprotein E in Alzheimer‘s disease. Neuron63(3) , 287–303 (2009).
  • Laskowitz DT , ThekdiAD, ThekdiSD et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol. 167(1) , 74–85 (2001).
  • Imbimbo BP , SolfrizziV, PanzaF. Are NSAIDs useful to treat Alzheimer‘s disease or mild cognitive impairment? Front. Aging Neurosci.2 , PII19 (2010)
  • Atwood CS , BishopGM, PerryG, SmithMA. Amyloid-beta: a vascular sealant that protects against hemorrhage? J. Neurosci. Res.70(3) , 356 (2002)
  • Zhang-Nunes SX , Maat-SchiemanML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol.16(1) , 30–39 (2006).
  • Pfeifer M , BoncristianoS, BondolfiL et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science 298(5597) , 1379 (2002).
  • Racke MM , BooneLI, HepburnDL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid beta. J. Neurosci. 25(3) , 629–636 (2005).
  • Wilcock DM , JantzenPT, LiQ, MorganD, GordonMN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience144(3) , 950–960 (2007).
  • Boche D , ZotovaE, WellerRO et al. Consequence of Abeta immunization on the vasculature of human Alzheimer‘s disease brain. Brain 131(Pt 12) , 3299–3310 (2008).
  • Patton RL , KalbackWM, EshCL et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer‘s disease patients: a biochemical analysis. Am. J. Pathol. 169(3) , 1048–1063 (2006).
  • Vellas B , BlackR, ThalLJ et al.; AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res.6(2) , 144–151 (2009).
  • Seubert P , Vigo-PelfreyC, EschF et al. Isolation and quantification of soluble Alzheimer‘s beta-peptide from biological fluids. Nature 359(6393) , 325–327 (1992).
  • Siemers ER , FriedrichS, DeanRA et al. Safety and changes in plasma and cerebrospinal fluid amyloid-beta after a single administration of an amyloid-beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33(2) , 67–73 (2010).
  • DeMattos RB , RackeMM, GelfanovaV et al. Identification, characterization, and comparison of amino-terminally truncated Abeta42 peptides in Alzheimer‘s disease brain tissue and in plasma from Alzheimer‘s patients receiving solanezumab immunotherapy treatment. Alzheimers Dement. 5 , P156–P157 (2009).
  • Seubert P , BarbourR, KhanK et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis. 5(2) , 65–71 (2008).
  • DeMattos RB , BalesKR, CumminsDJ et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer‘s disease. Proc. Natl Acad. Sci. USA 98(15) , 8850–8855 (2001).
  • Dodart JC , BalesKR, GannonKS et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer‘s disease model. Nat. Neurosci. 5(5) , 452–457 (2002).
  • DeMattos RB , BalesKR, CumminsDJ et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer‘s disease. Science 295(5563) , 2264–2267 (2002).
  • Levites Y , SmithsonLA, PriceRW et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer‘s disease mouse models. FASEB J. 20(14) , 2576–2578 (2006).
  • Yamada K , YabukiC, SeubertP et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 29(36) , 11393–11398 (2009).
  • Siemers ER , FriedrichS, DeanRA et al. P4–346: safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer‘s disease. Alzheimers Dement. 4 , T774 (2008).
  • Racke MM , BooneLI, HepburnDL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25(3) , 629–636 (2005).
  • Schroeter S , KhanK, BarbourR et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28(27) , 6787–6793 (2008).
  • Nicholas T , KnebelW, GastonguayMR et al. Preliminary population pharmacokinetic modeling of PF-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer‘s disease. Alzheimers Dement. 5 , P253 (2009).
  • Watts RJ , ChenM, AtwalJ et al. Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo. Alzheimers Dement. 5 , P426 (2009).
  • Relkin NR . Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin. Alzheimers Dement.4 , T101 (2008).
  • Dodel R , HampelH, DepboyluC et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer‘s disease. Ann. Neurol. 52(2) , 253–256 (2002).
  • Du Y , DodelR, HampelH et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57(5) , 801–805 (2001).
  • Britschgi M , OlinCE, JohnsHT et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer‘s disease. Proc. Natl Acad. Sci. USA 106(29) , 12145–12150 (2009).
  • Istrin G , BosisE, SolomonB. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide. J. Neurosci. Res.84(2) , 434–443 (2006).
  • Du Y , WeiX, DodelR et al. Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity. Brain 126(Pt 9) , 1935–1939 (2003).
  • Ma QL , LimGP, Harris-WhiteME et al. Antibodies against β-amyloid reduce Aβ oligomers, glycogen synthase kinase-3β activation and τ phosphorylation in vivo and in vitro. J. Neurosci. Res. 83(3) , 374–384 (2006).
  • Taguchi H , PlanqueS, NishiyamaY et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J. Biol. Chem. 283(52) , 4714–4722 (2008).
  • Fillit H , HessG, HillJ et al. Iv immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73(3) , 180–185 (2009).
  • Kountouris D . Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J. Neural Transm.5 , 18 (2000).
  • Dodel RC , DuY, DepboyluC et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer‘s disease. J. Neurol. Neurosurg. Psychiatry 75(10) , 1472–1474 (2004).
  • Relkin NR , SzaboP, AdamiakB et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30(11) , 1728–1736 (2009).
  • Kayed R , HeadE, ThompsonJL et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618) , 486–489 (2003).
  • Gotz J , IttnerLM. Animal models of Alzheimer‘s disease and frontotemporal dementia. Nat. Rev. Neurosci.9(7) , 532–544 (2008).
  • Meraz-Rios MA , Lira-De Leon KI, Campos-Pena V, De Anda-Hernandez MA, Mena-Lopez R. Tau oligomers and aggregation in Alzheimer‘s disease. J. Neurochem.112(6) , 1353–1367 (2010).
  • Rosenmann H , MeinerZ, GeylisV et al. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer‘s disease and healthy subjects. Neurosci. Lett. 410(2) , 90–93 (2006).
  • Solomon B . Immunological approach for the treatment of Alzheimer‘s disease. J. Mol. Neurosci.20(3) , 283–286 (2003).
  • Taniguchi S , SuzukiN, MasudaM et al. Inhibition of heparin induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280(9) , 7614–7623 (2005).
  • Taniguchi T , SumidaM, HiraokaS et al. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett. 579(6) , 1399–1404 (2005).
  • von Bergen M , FriedhoffP, BiernatJ, HeberleJ, MandelkowEM, MandelkowE. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc. Natl Acad. Sci. USA97(10) , 5129–5134 (2000).
  • Boutajangout A , IngadottirJ, DaviesP, SigurdssonEM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem.118(4) , 658–667 (2011).
  • Greenberg SG , DaviesP, ScheinJD, BinderLI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem.267(1) , 564–569 (1992).
  • Lasagna-Reeves CA , Castillo-CarranzaDL, JacksonGR, KayedR. Tau oligomers as potential target for immunotherapy for Alzheimer disease and tauopathies. Curr. Alzheimer Res.8(6) , 659–665 (2011).
  • Billings LM , OddoS, GreenKN, McGaughJL, LaFerlaFM. Intraneuronal Abeta causes the onset of early Alzheimer‘s disease related cognitive deficits in transgenic mice. Neuron45(5) , 675–688 (2005).
  • Masliah E , RockensteinE, AdameA et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson‘s disease. Neuron 46(6) , 857–868 (2005).
  • Tampellini D , MagraneJ, TakahashiRH et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem. 282(26) , 18895–18906 (2007).
  • Southwell AL , KoJ, PattersonPH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington‘s disease. J. Neurosci.29(43) , 13589–13602 (2009).
  • Roberson ED , Scearce-LevieK, PalopJJ et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer‘s disease mouse model. Science 316(5825) , 750–754 (2007).
  • Bateman RJ , SiemersER, MawuenyegaKG et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann. Neurol. 66(1) , 48–54 (2009).
  • Castellani RJ , LeeHG, SiedlakSL et al. Reexamining Alzheimer‘s disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J. Alzheimers Dis. 18(2) , 447–452 (2009).
  • Castellani RJ , LeeHG, ZhuX, NunomuraA, PerryG, SmithMA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol.111(6) , 503–509 (2006).
  • Lee EB , LengLZ, ZhangB et al. Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. 281(7) , 4292–4299 (2006).
  • Lambert MP , VelascoPT, ChangL et al. Monoclonal antibodies that target pathological assemblies of Aβ. J. Neurochem. 100(1) , 23–35 (2007).
  • Dubois B , FeldmanHH, JacovaC et al. Research criteria for the diagnosis of Alzheimer‘s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8) , 734–746 (2007).
  • Dubois B , FeldmanHH, JacovaC et al. Revising the definition of Alzheimer‘s disease: a new lexicon. Lancet Neurol. 9(11) , 1118–1127 (2010).
  • McKhann GM , KnopmanDS, ChertkowH et al. The diagnosis of dementia due to Alzheimer‘s disease. Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer‘s disease. Alzheimers Dement. 7(3) , 263–269 (2011).
  • Albert MS , DekoskyST, DicksonD et al. The diagnosis of mild cognitive impairment due to Alzheimer‘s disease. Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer‘s disease. Alzheimers Dement. 7(3) , 270–279 (2011).
  • Sperling RA , AisenPS, BeckettLA et al. Toward defining the preclinical stages of Alzheimer‘s disease. Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer‘s disease. Alzheimers Dement. 7(3) , 280–292 (2011).
  • Weiner MW , AisenPS, JackCR Jr et al; Alzheimer‘s Disease Neuroimaging Initiative. The Alzheimer‘s disease neuroimaging initiative. progress report and future plans. Alzheimers Dement.6(3) , 202–211 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.